BeyondSpring to Host First Quarter Financial Results and Corporate Update Conference Call on June 16, 2021
06/11/2021 - 08:00 AM
NEW YORK, June 11, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (“BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that management will host a conference call to report its financial results for the first quarter ended March 31, 2021 and provide an update on recent corporate events on June 16, 2021 at 8:30 AM Eastern Time.
The conference call may be accessed by dialing 877-451-6152 (U.S.) or 201-389-0879 (International) and referencing conference ID: 13720525. A live webcast will be available on BeyondSpring’s website at www.beyondspringpharma.com under “Events & Presentations” in the Investors section. An archived replay of the webcast will be available for 90 days.
About BeyondSpring Selective Immunomodulating Microtubule-Binding Agent (SIMBA), is a “pipeline in a drug.” It is filed for approval with Priority Review in the U.S. and China for the prevention of chemotherapy-induced neutropenia (CIN) and has a fully enrolled pivotal study (Dublin-3) to test an anti-cancer benefit with an overall survival primary endpoint in non-small cell lung cancer (NSCLC). Additionally, it is being broadly studied in combination with various immuno-oncology agents that could boost the effects of PD-1 / PD-L1 antibodies. In addition to plinabulin, BeyondSpring’s extensive pipeline includes three pre-clinical immuno-oncology assets and a subsidiary, SEED Therapeutics, which is leveraging a proprietary targeted protein degradation drug discovery platform.
Investor Contact: arr@lifesciadvisors.com
Media Contact: darren@lifescicomms.com
BYSI Rankings
#491 Ranked by Stock Gains
BYSI Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Health Technology, Pharmaceuticals: Major, Manufacturing, Pharmaceutical Preparation Manufacturing
About BYSI
beyondspring pharmaceuticals is a clinical stage biopharmaceutical company focused on the development of innovative cancer therapies. we are currently advancing the development of our lead asset plinabulin, a novel cancer therapeutic, in a global phase 3 trial in non-small-cell lung cancer (nsclc) and initiating a pivotal global phase 3 trial in prevention of docetaxel-induced neutropenia. as a tubulin depolymerizing agent, plinabulin works via multiple mechanisms of action to target and alter the tumor microenvironment: 1. immune enhancing effects via dendritic cell maturation 2. tumor cell apoptosis via activation of ras-jnk pathway 3. vascular disruptive effects given plinabulin’s potential as a tumor micro-environment targeting agent, we intend to initiate clinical trials in additional cancer indications: • immuno-oncology, with immune checkpoint inhibitors in nsclc • cns malignancies including glioblastoma (gbm) • kras positive mutant cancers
